Not applicable—this is a category description rather than a defined molecular target (Not applicable)

The term "tumor-associated antigens derived from patient-specific tumor proteins" imprecisely combines two distinct concepts in cancer immunotherapy. Tumor-associated antigens (TAAs) are normal proteins overexpressed in cancer cells but also present in some healthy tissues, making them shared targets across patients rather than patient-specific. In contrast, true patient-specific antigens are tumor-specific antigens (TSAs)—novel protein sequences generated from tumor mutations that are unique to each individual's cancer. While both TAAs and TSAs are targeted in immunotherapies, including monoclonal antibodies, bispecific antibodies, CAR-T cell therapy, and cancer vaccines, they require fundamentally different therapeutic approaches and carry distinct safety profiles. TAA targeting risks autoimmunity, while TSA identification requires personalized molecular analysis using genomics, immunopeptidomics, and prediction algorithms. This target description requires clarification to specify whether TAAs or TSAs are intended, and if TAAs, which specific molecule (e.g., mesothelin, claudin 18.2, MAGE) is the actual therapeutic target.

Other names

Tumor-associated antigen (TAA)

Antibody-dependent cellular cytotoxicity (ADCC); T cell redirection; Immune activation; Checkpoint inhibition; Neoantigen presentation